Eisai, Salix team up to push Colazal

Share this article:
Salix Pharmaceuticals and Eisai have entered into a multi-year co-promotion deal to promote Salix's ulcerative colitis treatement Colazal (balsalazide disodium).

Financial terms of the deal were not disclosed.

Eisai's primary care and specialty sales forces will help Salix promote Colazal to primary care physicians and gastroenterologists. Approximately 600 Eisai sales reps will be added to the field force of 96 Salix reps, beginning in late October, an Eisai spokeswoman told MM&M.

Eisai also has exclusive rights to be involved in promotion of an 1100 mg. version of Colazal, pending product approval, Eisai said.  

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.